MET Targeted Therapy for NSCLC

EP. 1: Impact of Driver Mutations in NSCLC

March 23rd 2020

EP. 2: Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC

March 23rd 2020

EP. 3: FDA Priority Review of Capmatinib for METex14-Mutated NSCLC

March 23rd 2020

EP. 4: The Availability of MET Inhibitors for NSCLC

March 23rd 2020

EP. 5: Benefit of Alpelisib/Fulvestrant Combo in HR+/HER- Breast Cancer Confirmed With Biomarker Analysis

ByBrittany Lovely

June 5th 2022

Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.

MET Targeted Therapy for NSCLC

EP. 1: Impact of Driver Mutations in NSCLC

EP. 2: Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC

EP. 3: FDA Priority Review of Capmatinib for METex14-Mutated NSCLC

EP. 4: The Availability of MET Inhibitors for NSCLC

EP. 5: Benefit of Alpelisib/Fulvestrant Combo in HR+/HER- Breast Cancer Confirmed With Biomarker Analysis

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer

Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma

Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes

Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD

Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance